Trial intelligence / Profile preview

Botox for treatment of infantile esotropia

2012-005068-82Phase 4Active

Sponsor: Het Oogziekenhuis Rotterdam
Start: Nov 2012
Modality: Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 4, single-arm trial of botulinum toxin type A in Congenital Esotropia (CE), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoint: Success rate of alignment at 6 months. Started Nov 2012; status: active.

Drugs

botulinum toxin type A

Conditions

Congenital Esotropia (CE)

Beyond the preview

Go deeper on 2012-005068-82.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-005068-82.